You will be responsible for our Pegozafermin asset, currently in Phase 3 for the treatment of MASH. Pegozafermin (FGF-21 analog) is our latest portfolio addition following the acquisition of 89Bio. Data readouts are expected from 2027, with the first filing expected soon after. Pegozafermin could be among the first launches in CVRM for Roche and represents a treatment option addressing significant unmet needs in a population with very limited current treatment options.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Industry
Professional, Scientific, and Technical Services
Number of Employees
5,001-10,000 employees